The leading articles for last week ran the gamut in terms of topics, but suggest investors are still worried
about inflation and remain interested in biotech, nuclear energy, and derivatives strategies.
Todd Shriber’s article highlighting the recent outsized performance of ALPS’s SBIO claimed the top spot. “This Biotech ETF’s Hot Start Can Continue” notes that the ALPS Medical Breakthroughs ETF (SBIO) was up 12% over a one-month period, driven by a well-run FDA approvals process and merger & acquisitions activity in the space.
Ben Hernandez’s article about a recent Nasdaq-sponsored event fell into the number two ranking. The piece, “Derivatives-Based Strategies Take Center Stage at Asset Allocation Summit,” focuses on the many ways derivatives can be used to respond to investor needs, with insights from representatives from Direxion Investments, JP Morgan Asset Management, Tuttle Capital, and Tidal Financial Group.
Given its popularity, “Tired of Sticky Inflation? Try This High-Income ETF,” by Nick Wodeshick, suggests that investors are still struggling with the effects of persistent inflation. It was the third-most-read article last week.
The interest around a certain type of nuclear energy company landed “Nuclear Growth: Why EPC Firms Are Key,” by Elle Fitzgerald, in the No. 4 spot. Engineering, procurement, and construction firms are expected to be crucial for future nuclear development.
Finally, “T. Rowe Price Value ETF Earns Morningstar Recognition,” by DJ Shaw, marked a major development for the $387 million T. Rowe Price Equity Income ETF (TEQI) as the fund earned its place on Morningstar’s list of the best active value ETFs for 2026. The article was the fifth-most read article from the week beginning April 19.
For more news, information, and analysis, visit VettaFi | ETFDB.
